ClinicalTrials.gg
CompletedNCT01595854Updated Aug 22, 2013Results posted

Investigation of Pharmacodynamic Effects of Dabigatran and Ticagrelor and Assessment of Ticagrelor Interaction Potential With Dabigatran

A Phase 1 interventional study of dabigatran etexilate and Ticagrelor in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Evaluation of potential ticagrelor effects on dabigatran exposure and evaluation of two new pharmacodynamic methods

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Test 2 (part 3)

    low dose dabigatran + high dose ticagrelor

    Drug: Ticagrelor · Drug: dabigatran etexilate

  • Active comparator
    Test 1 (part 1 + 2)

    high dose ticagrelor

    Drug: Ticagrelor

  • Experimental
    Reference 1 (part 1 + 2)

    medium dose dabigatran

    Drug: dabigatran etexilate

  • Experimental
    Reference 2 (part 3)

    low dose dabigatran

    Drug: dabigatran etexilate

Interventions

  • Drugdabigatran etexilate

    medium dose dabigatran

  • high dose ticagrelor

  • high dose ticagrelor

  • Drugdabigatran etexilate

    low dose dabigatran

  • Drugdabigatran etexilate

    medium dose dabigatran

06

What researchers measure

Primary outcomes

  1. Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.

    Time frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours

  2. Total Dabigatran: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of total dabigatran in plasma, per period.

    Time frame: -1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours

Secondary outcomes

  1. Number of Participants With Drug Related Adverse Events

    The number of participants with drug related adverse events

    Time frame: From screening until the end-of-study examination

07

Results

Posted Aug 22, 2013

Participant flow

Participant flow — Overall Study
MilestoneDabigatran Etexilate 220 mg - Part 1Ticagrelor 180 mg - Part 1Dabigatran Etexilate 220 mg - Part 2Ticagrelor 180 mg - Part 2Dabigatran Etexilate/Multiple Dose Ticagrelor Crossover-Part 3
Started848412
Completed848412
Not completed00000

Outcome measures

PrimaryTotal Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the concentration-time curve of the analyte in plasma, over the time interval from 0 extrapolated to infinity, of dabigatran.

Time frame:
-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours
Reported as:
Geometric mean · ng*h/mL
Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)
ng*h/mLDabi 75 mgDabi + Ticagrelor LDDabi + Ticagrelor MD
Total Dabigatran (Dabi): Area Under the Curve 0 to Infinity (AUC0-∞)281.05 ± 104485.48 ± 40.5410.46 ± 53.1
PrimaryTotal Dabigatran: Maximum Measured Concentration (Cmax)

Maximum measured concentration of total dabigatran in plasma, per period.

Time frame:
-1/-0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours
Reported as:
Geometric mean · ng/mL
Total Dabigatran: Maximum Measured Concentration (Cmax)
ng/mLDabi 75 mgDabi + Ticagrelor LDDabi + Ticagrelor MD
Total Dabigatran: Maximum Measured Concentration (Cmax)31.47 ± 13061.30 ± 42.949.11 ± 64.8
SecondaryNumber of Participants With Drug Related Adverse Events

The number of participants with drug related adverse events

Time frame:
From screening until the end-of-study examination
Reported as:
Number · participants
Number of Participants With Drug Related Adverse Events
participantsDabigatran 220 mg - Part 1Ticagrelor 180 mg - Part 1Dabigatran 220 mg - Part 2Ticagrelor 180 mg - Part 2Dabigatran 75 mg - Part 3Dabigatran + Ticagrelor - Part 3
Number of Participants With Drug Related Adverse Events000001

Adverse events

Collected over 3 to 10 days after last dosing. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dabigatran Etexilate 220 mg - Part 1—0/8 (0%)1/8 (12.5%)
Ticagrelor 180 mg - Part 1—0/4 (0%)0/4 (0%)
Dabigatran Etexilate 220 mg - Part 2—0/8 (0%)0/8 (0%)
Ticagrelor 180 mg - Part 2—0/4 (0%)0/4 (0%)
Dabi 75 mg - Part 3—0/12 (0%)2/12 (16.7%)
Multiple Dose Ticagrelor - Part 3—0/12 (0%)3/12 (25%)
Most frequent other events
Most frequent other events
EventDabigatran Etexilate 220 mg - Part 1Ticagrelor 180 mg - Part 1Dabigatran Etexilate 220 mg - Part 2Ticagrelor 180 mg - Part 2Dabi 75 mg - Part 3Multiple Dose Ticagrelor - Part 3
Gastrointestinal infectionInfections and infestations1/80/40/80/40/120/12
NauseaGastrointestinal disorders0/80/40/80/40/121/12
Neck painMusculoskeletal and connective tissue disorders0/80/40/80/41/121/12
ErythemaSkin and subcutaneous tissue disorders0/80/40/80/40/121/12
RashSkin and subcutaneous tissue disorders0/80/40/80/41/120/12

Baseline characteristics

Age Continuous
Age Continuous(years)Dabigatran Etexilate 220 mg - Part 1Ticagrelor 180 mg - Part 1Dabigatran Etexilate 220 mg - Part 2Ticagrelor 180 mg - Part 2Dabigatran Etexilate / Multiple Dose Ticagrelor - Part 3Total
Mean30.6 ± 7.729.8 ± 11.433.6 ± 9.133.3 ± 6.330.2 ± 7.231.3 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Dabigatran Etexilate 220 mg - Part 1Ticagrelor 180 mg - Part 1Dabigatran Etexilate 220 mg - Part 2Ticagrelor 180 mg - Part 2Dabigatran Etexilate / Multiple Dose Ticagrelor - Part 3Total
Female000000
Male84841236
08

Study locations

1 site
  • 1160.141.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2012
First posted
May 10, 2012
Start
May 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Aug 22, 2013
Last update
Aug 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01595854
Responsible party
Sponsor
First posted
May 10, 2012
Start date
May 2012
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Aug 22, 2013
Last update
Aug 22, 2013

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion